



PERSONALIZED
MEDICINE COALITION

MEMBERSHIP PROSPECTUS

The Personalized Medicine Coalition, representing innovators, scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and health systems.



PARADIGM SHIFTS, ESPECIALLY IN MEDICINE, DO NOT HAPPEN JUST BECAUSE THE SCIENCE AND NEW TECHNOLOGIES SUGGEST THEY SHOULD.

Based on this assumption, some 20 institutions launched the Personalized Medicine Coalition in 2004 to develop a new medical paradigm that links treatment decisions to diagnostics.

Believing in an ecosystem of shared value across the multiple stakeholders it represents, the Coalition advocates for changes that will increase investment in personalized medicine and facilitate its clinical adoption so that both patients and health systems will benefit from improved health care and increased efficiency.

WHAT IS PERSONALIZED MEDICINE?

Personalized medicine is an evolving field in which physicians use diagnostic tests to determine which medical treatments will work best for each patient or use medical interventions to alter molecular mechanisms that impact health. By combining data from diagnostic tests with an individual's medical history, circumstances and values, health care providers can develop targeted treatment and prevention plans with their patients.

PMC WORKS TO ENSURE THAT POLICIES AND PRACTICES IN THE PUBLIC AND PRIVATE SECTORS PAVE THE WAY FOR PERSONALIZED MEDICINE.

Based in Washington, D.C., PMC works closely with health systems, lawmakers and agency officials to advance strategic priorities in three areas:

- **Education:** To raise the profile and scope of personalized medicine, PMC proactively educates decision-makers and patients about how the field can make health systems more effective and efficient by targeting better treatments to only those who will benefit.
- **Advocacy:** To help facilitate the development of personalized medicine tests and therapies, PMC engages policymakers to advocate for continued investments in biomedical research as well as modernized regulatory, coverage and payment policies that support access to personalized medicine.
- **Evidence Development:** To encourage the swifter adoption of personalized medicine by payers and health care providers, PMC helps build the evidence base necessary to demonstrate the clinical and economic value of personalized medicine.

“Personalized medicine is transforming the practice of medicine, and PMC is playing a critical role in bringing together all of the stakeholders to help make that happen.”

– Raju Kucherlapati, Ph.D., Paul C. Cabot Professor of Genetics, Harvard Medical School

PMC MEMBERS ARE LEADING THE MOVEMENT TOWARD PERSONALIZED MEDICINE TO BENEFIT PATIENTS AND HEALTH SYSTEMS AROUND THE WORLD.

MEMBER COMMITTEES/WORKING GROUPS

- **Public Policy Committee**
 - Patient Advocacy Organization Working Group
 - Pharmaceutical and Diagnostics Working Group
- **Science Policy Committee**
 - Health Care Working Group
 - Value Assessment Working Group
- **Additional Working Groups**
 - Health Data Working Group
 - Pharmacogenomics Working Group

MEMBER BENEFITS

Contact
2,000+

leaders in personalized medicine via PMC's member database

Interact with
200+

thought leaders from Congress, FDA, CMS and the private sector at member meetings and events

Save
40%

on registration for the *Annual Personalized Medicine Conference*

Attend Member Meetings and Events

at no charge

Receive Copies

of PMC publications and reports

PMC MEMBERSHIP

PMC is an international, multi-stakeholder 501(c)3 nonprofit organization with members that are committed to science-driven, evidence-based health care.

CLINICAL LABORATORY TESTING SERVICES

Blue Genes
Invitae
Laboratory Corporation
of America (Labcorp)
Quest Diagnostics
SmartLabs

DIAGNOSTIC COMPANIES

10x Genomics
Agendia NV
Agilent Technologies
Biological Dynamics
Castle Biosciences
Circulogene
Cofactor Genomics
Delfi Diagnostics
Exact Sciences
Exai Bio
Foundation
Medicine, Inc.
GeneCentric
Therapeutics
GRAIL, Inc.
Guardant Health
Illumina
Myriad Genetics
NanoString
Technologies
NeoGenomics
Laboratories
Olaris, Inc.
Oncocyte
Quibim
Roche Diagnostics
Singular Genomics
SomaLogic, Inc.
Thermo Fisher Scientific

EMERGING BIOTECH/ PHARMACEUTICAL COMPANIES

1cBio
Actio Biosciences
Adaptive
Biotechnologies
Alexion Pharmaceuticals
Day One Bio

Denovo Biopharma
Elevation Oncology, Inc.
Freenome
Helix
ImmunoGen
Jazz Pharmaceuticals
Kyverna Therapeutics
Merus
OneOme
Rapafusyn
Pharmaceuticals

HEALTH INSURANCE COMPANIES

Point32Health

INDUSTRY/TRADE ASSOCIATIONS

American Clinical
Laboratory Association
Biocom California
National Society of
Genetic Counselors
PhRMA

IT/INFORMATICS COMPANIES

Aetion
Aitia
Arancia
Assurance Health Data
Aster Insights
BC Platforms
Change Healthcare
Concert Genetics
DNAnexus
Flatiron Health
Nucleai
Oxford Nanopore
Technologies
PathAI
Syapse
Translational Software
Verily Life Sciences

LARGE BIOTECH/ PHARMACEUTICAL COMPANIES

AbbVie
Amgen, Inc.
Astellas

AstraZeneca
Pharmaceuticals
Bausch Health
Companies
Biogen
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly and Company
Genentech, Inc.
Gilead
GlaxoSmithKline
Johnson & Johnson
Merck & Co.
Novartis
Pfizer, Inc.
Sanofi

PATIENT ADVOCACY GROUPS

Accelerated Cure
Project for
Multiple Sclerosis
AiArthritis
Alliance for Aging
Research
Alzheimer's Foundation
of America
American Association
of Kidney Patients
(AAKP)
American Cancer
Society Cancer Action
Network (ACS-CAN)
Bulgarian Association
for Personalized
Medicine
Cancer Treatment
Options &
Management Inc.
(CTOAM)
Colorectal Cancer
Alliance
Emily's Entourage
EveryLife Foundation
for Rare Disease
Friends of Cancer
Research
Glioblastoma
Foundation
Global Liver Institute
GO2 for Lung Cancer
International Cancer
Advocacy Network

KRAS Kickers
LUNGeVity Foundation
Multiple Myeloma
Research Foundation
National Alliance
Against Disparities in
Patient Health
National Alliance for
Hispanic Health
National Health
Council
National Pancreas
Foundation
Rabble Health
Sepsis Alliance
Support Fibromyalgia
Network
SynGAP Research Fund
TargetCancer
Foundation
Team Trevor
The Assistance Fund

**PERSONALIZED
MEDICINE
SERVICE PROVIDERS**

CareDx
Coriell Life Sciences
InformedDNA
Michael J. Bauer, M.D.,
& Associates, Inc.
My Gene Counsel
QURE Healthcare
Tempus

**RESEARCH,
EDUCATION &
CLINICAL CARE
INSTITUTIONS**

AcceleVirDx
AdventHealth
American Association
for Cancer Research
(AACR)
American Medical
Association (AMA)
American Society
of Health System
Pharmacists (ASHP)
Arizona State
University
Association for
Molecular
Pathology (AMP)
Audubon Bioscience
Business Finland
Cancer Treatment
Centers of America
Cedars-Sinai

Clarified Precision
Medicine
Codex4SMEs
Colorado Center for
Personalized Medicine
CommonSpirit Health
Coriell Institute for
Medical Research
Culmination Bio
Duke Center for
Research
Essentia Institute of
Rural Health
European
Infrastructure for
Translational Medicine
(EATRIS)
Genome Canada
Hamad Medical
Corporation
Hospital Albert Einstein
iCAN – Digital
Precision Cancer
Medicine at University
of Helsinki
Intermountain
Healthcare
King Faisal Specialist
Hospital and Research
Centre
MaineHealth
Accountable Care
Organization
Manchester University
School of Pharmacy
Marshfield Clinic
Mayo Clinic
MD Anderson
– Institute for
Personalized Cancer
Therapy
Moffitt Cancer Center
Morehouse School
of Medicine
National
Pharmaceutical
Council
Nicklaus Children’s
Hospital
Research Institute
North Carolina
Biotechnology
Center (NCBIO)
NorthShore University
Parkview Health
Qatar Biobank
Sanford Imagenetics,
Sanford Health
Teachers’ Retirement
System of Kentucky

The Christ Hospital
The Jackson Laboratory
Translational Genomics
Research Institute
(Tgen)
UC Davis Mouse
Biology Program
University of Alabama,
Birmingham
University of California,
San Francisco (UCSF)
University of Chicago
University of
Pennsylvania Health
System
University of Pittsburgh
Medical Center
(UPMC)
University of South
Florida Morsani
College of Medicine

**RESEARCH TOOL
COMPANIES**

Octave Biosciences

**STRATEGIC
PARTNERS**

ADVI
Arnold & Porter
Avalere
Bradford Power
Bruce Quinn Associates
Cambridge Healthtech
Institute
Carol Colman
Catalytic Agency
Clinical Transformation
Partners
ConText
ConvergeHEALTH
by Deloitte
Deverka Consulting
Diaceutics
Foley & Lardner, LLP
Foley Hoag, LLP
Genome Creative
Goldbug Strategies,
LLC
Harbor Precision
Genomics
Health Advances, LLC
Innovation Horizons
Innovation Policy
Solutions
KPMG
L.E.K. Consulting
McDermott Will &
Emery

Morrison Foerester
Prasanth Reddy, M.D.,
M.P.H., F.A.C.P.
Priya Hays, M.D.,
Ph.D.
Reservoir
Communications
Slone Partners
SolarisRTC

The Synergist
Trusted Health
Advisors
United States
Pharmacopeial
Convention (USP)
Veranex Solutions
W.J. Pignato &
Associates, LLC

William P. Stanford,
M.D., Ph.D.

VENTURE CAPITAL

Andreessen Horowitz
GreyBird Ventures, LLC
RA Capital Management
Section 32
Third Rock Ventures, LLC

DUES STRUCTURE

As of January 2024

Large Public Corporation	\$38,000
Small Public Corporation	\$19,000
Trade Association	(based on revenues)
Private Corporation >15 FTEs	\$7,150
Private Corporation <15 FTEs	\$3,500
Strategic Partner >5 FTEs	\$3,700
Strategic Partner <5 FTEs	\$1,700
Research, Education & Clinical Care Institutions	\$3,500
Patient Advocacy Group	\$500

Visit members.personalizedmedicinecoalition.org
to join the Coalition.

For more information, contact Kayla Brown,
Vice President, Membership & Development,
at kbrown@personalizedmedicinecoalition.org.

STAFF

Edward Abrahams, Ph.D.
President

Faswilla Sampson, M.S.
Chief Operating Officer

Cynthia A. Bens
*Senior Vice President,
Public Policy*

Daryl Pritchard, Ph.D.
*Senior Vice President,
Science Policy*

Christopher J. Wells, M.P.A.
Senior Vice President, Public Affairs

Kayla Brown
*Vice President, Membership &
Development*

David L. Davenport
Manager, Public and Science Policy

Lindsay Stephens
*Director, Operations & Secretary
to the Board*

BOARD OF DIRECTORS

Lincoln Nadauld, M.D., Ph.D.
Chair
CEO, Culmination Bio

Lauren Silvis, J.D.
Vice Chair
Tempus

Peter Maag, Ph.D.
Treasurer
Kyverna Therapeutics

Michael Sherman, M.D.
Secretary
RA Capital Management

Gabriele Allegri
Johnson & Johnson Innovative
Medicine

Antonio L. Andreu, M.D., Ph.D.
European Infrastructure
for Translational Medicine
(EATRIS)

Randy Burkholder
PhRMA

Dawn Cardeiro
Point32Health

Brian Caveney, M.D.
Labcorp

William S. Dalton, Ph.D., M.D.
Aster Insights

Stephen L. Eck, M.D., Ph.D.
MacroGenics

Helmy Eltoukhy, Ph.D.
Guardant Health

Lori Frank, Ph.D.
The New York Academy of Medicine

Sarah Hersey
Bristol Myers Squibb

Steffan Ho, M.D., Ph.D.
Pfizer

Richard Knight
American Association of Kidney
Patients

Mia Levy, M.D., Ph.D.
Foundation Medicine

James W. Lillard, Ph.D.
Morehouse School of Medicine

Howard McLeod, Pharm.D.
Clarified Precision Medicine

J. Brian Munroe
Bausch Health Companies Inc.

Elizabeth O'Day, Ph.D.
Olaris, Inc.

Joshua Ofman, M.D.
Grail

Prasanth Reddy, M.D.

**Apostolia-Maria Tsimberidou,
M.D., Ph.D.**
The University of Texas MD
Anderson Cancer Center

Michael J. Vasconcelles, M.D.
ImmunoGen

Jay G. Wohlgemuth, M.D.
Trusted Health Advisors



PERSONALIZED
MEDICINE COALITION

1710 Rhode Island Ave., NW, Suite 700
Washington, DC 20036

pmc@personalizedmedicinecoalition.org